Navigation Links
Genedata Announces Collaboration With AstraZeneca on the Analysis of Compound Combination Experiments
Date:12/3/2013

nentially with the number of compounds to be compared. Genedata Screener effectively addresses the data analysis challenges of these large data sets by enabling researchers to:
  • Go from raw data to results in less than 30 minutes, also for large studies
  • Eliminate time-consuming manual data processing
  • Interactively inspect raw data and check the quality of normalized values
  • Review in-depth intermediate and final results using combination-specific displays such as concentration matrices and isobolograms
  • Automatically fit both mono-therapeutic and combination dose-response curves for quick and robust results
  • Display, quantify and compare measured and expected combination effects for different interaction models such as Loewe, Highest Single Agent, or Bliss
  • Access all processing steps throughout the workflow
“We see a huge demand for software that efficiently analyzes compound combination experiments in novel drug discovery,” said Dr. Othmar Pfannes, CEO of Genedata. “Our successful collaboration with AstraZeneca, a leader in combination therapies, helps us to further advance Genedata Screener as the platform of choice for the efficient analysis of compound combination experiments.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biogas Consortium Using Genedata Selector for Metagenomics-based Process Optimization
2. Sanofi Adopts Genedata Biologics for Integrated Biopharma R&D Process Support
3. Evonik and Genedata Broaden Their Collaboration with the Genedata Selector Biotechnology Data Management Platform
4. Genedata Screener Global User Group Meetings Will Examine Advancements in Plate-based Screening
5. Genedata Screener Extends Support for High-Throughput Thermofluor Assays
6. Genedata at ESACT Announces Expansion Into Biopharma Process Development
7. New Genedata Expressionist for Mass Spectrometry Showcases at 2013 ASMS
8. AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization
9. Genedata Biologics for Biopharma R&D at Ninth Annual PEGS
10. Genedata Screener 11 with Compound Combination Screening and Collaboration in the Cloud Announced at Bio-IT World 2013
11. Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 In November 2012, the European ... Evaluation Report (PBRER) in a new PSUR – responding to ... benefit-risk profile of a drug. Adopted in many regions, the ... Present a comprehensive and critical analysis of new or ... Highlight any new evidence of the potential benefits of ...
(Date:8/19/2014)... AZ (PRWEB) August 19, 2014 Sales ... launch of its online sales skills training course ... sales skills. , MedTech clinical staff spend the majority ... a hospital, standalone medical center, or physician practice – ... staff. But why stop there? Sales Horizons believes clinical ...
(Date:8/18/2014)... , Aug. 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. ... commercializes proprietary technologies and products for advanced microarray diagnostics, ... on Friday, August 22 at 2:00 pm ET.  ... CEO, will provide a brief review of SQI,s recent ... , a diagnostics industry veteran recently appointed to the ...
(Date:8/18/2014)... devices with unprecedented efficiency and data storage ... use built-in electric polarizations to read and ... most popular data-driven technology. But ferroelectrics must ... including a curious habit of "forgetting" stored ... U.S. Department of Energy,s Brookhaven National Laboratory ...
Breaking Biology Technology:Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4
... Provides HIV-Resistant Immune CellsRICHMOND, Calif., Feb. 3 Sangamo ... that its collaborators at the University of Pennsylvania ... evaluate SB-728-T for the treatment of HIV/AIDS. Based on ... has been shown in an animal model of ...
... face of a recession is no small feat for any company. ... Sudberg called "being in the right place at the right time" and ... ... CA (PRWEB) February 2, 2009 -- Sidney Sudberg, Founder, CEO and Chief ...
... 2 Since the cloning of Dolly the ... has been considered a promising way to generate human, patient-specific ... eggs has led to efforts to substitute animal oocytes. However, ... Volume 11, Number 2, 2009 issue of Cloning and ...
Cached Biology Technology:Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 2Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 3Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 4Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 5Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 6Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 7Alkemists Labs Wins Nutrition Business Journal's 2008 Industry Growth Award 2Alkemists Labs Wins Nutrition Business Journal's 2008 Industry Growth Award 3Animal Eggs Not Suitable Substitutes to Produce Stem Cells 2Animal Eggs Not Suitable Substitutes to Produce Stem Cells 3
(Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million ... four researchers at the University of Massachusetts Medical School, ... (SCID) can be successfully implemented across public health newborn ... in the Aug. 20 issue of the Journal ... showed the rate of SCID in newborns is higher ...
(Date:8/20/2014)... Ore. -- When are athletes who have suffered concussions ... Oregon study has found that high school athletes who ... 60 days experience a significant regression in their abilities ... The regression, as seen in changes in their balance ... 19 athletes. Ten of the 12 had returned to ...
(Date:8/20/2014)... bags could one day be made out of cocoa, ... now reporting. The novel process they developed and their ... agricultural and plastic waste problems, appear in the ACS ... Bayer and colleagues at the Italian Institute of Technology ... 2012, its production reached 288 million tons worldwide, but ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... SPRING HARBOR, N.Y. (Nov. 12, 2008) For ... for written exams on theoretical concepts, it can be ... skills used in the clinic. The third edition ... for these daunting practical-skills tests, Clinical Skills for ...
... is proud to acknowledge the work of 12 outstanding ... new ideas, recognize leadership in gerontological teaching and service, ... award presentations will take place at GSA,s 61st Annual ... 2008, in National Harbor, MD , at the ...
... November 09, 2008─Bronx, NY─ In a breakthrough study appearing ... researchers at Albert Einstein College of Medicine of Yeshiva ... viewing individual breast cancer cells for several days at ... Lipper Biophotonics Center, provides detail on how cancer cells ...
Cached Biology News:New book helps medical students master clinical skills 2GSA congratulates 2008 award winners 2GSA congratulates 2008 award winners 3Einstein researchers develop a new way to study how breast cancer spreads 2Einstein researchers develop a new way to study how breast cancer spreads 3
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
... Zeba Desalt Spin Columns contain a ... that offers exceptional desalting and protein-recovery characteristics ... containing as low as 25 g/ml of ... recovery and > 95% retention of salts ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
... Synthetic peptide corresponding to ... Antigen Family: Regulator ... Subfamily: not assigned-Regulator ... Storage: Long term: ...
Biology Products: